Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/2/2026

1. NKE
2. TSLA
3. SPCX
4. META
5. MU
6. SPY
7. ABVX
8. NVDA
9. BE
10. STZ

Go back to Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Regeneron (NASDAQ: REGN) Delayed: 624.72 +1.18 (0.19%)
Previous Close $623.54    52 Week High $592.36 
Open $629.90    52 Week Low $325.35 
Day High $632.85    P/E 163.97 
Day Low $623.89    EPS $3.81 
Volume 1,170,658       

Regeneron (NASDAQ: REGN) Delayed: 624.72 +1.18 (0.19%)
Previous Close $623.54    52 Week High $592.36 
Open $629.90    52 Week Low $325.35 
Day High $632.85    P/E 163.97 
Day Low $623.89    EPS $3.81 
Volume 1,170,658